Here are the 10-Q quarterly reports from iTeos Therapeutics, Inc. (ITOS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ITOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ITOS filings page.
Overview The Company disclosed termination of the GSK collaboration and the belrestotug program (GSK Termination Notice dated 2025-05-13; Mutual Termination Agreement dated 2025-07-18 with a $32.0 million settlement payable). On 2025-05-28 the Company announced intent to wind down clinical and operational activities, expected substantially complete in Q3 2025. The registrant reported substantial doubt about its ability to continue as a going concern as of the issuance date of these financial statements (2025-08-06).
Key financials
- Cash and cash equivalents: $207.820 million; short-term investments: $307.610 million; long-term investments: $74.614 million; total assets: $623.083 million.
- Total liabilities: $129.282 million; unrecognized tax benefits: $48.790 million; grants repayable: $6.606 million.
- Six months ended 6/30/2025 net loss: $113.341 million; three months ended 6/30/2025 net loss: $78.729 million; basic net loss per share: $(2.61) six months, $(1.81) quarter.
- Operating highlights: R&D expense $86.314 million YTD; restructuring costs $16.335 million in the quarter; license and collaboration revenue $0 in 2025 vs $35.0 million in H1 2024.